Bio


Dr. Jessica Ruiz is a pediatric endocrinologist and Instructor at Stanford University and the Lucile Packard Children’s Hospital.

As a pediatrician-scientist and bioengineer, Dr. Ruiz's scholarly interest is pediatric type 2 diabetes. Her passion is to better predict, prevent and treat type 2 diabetes through digital phenotyping. Dr. Ruiz's vision is to apply data science and machine learning approaches to continuous glucose monitoring (CGM) data. Her work seeks to parameterize glucose kinetics to ultimately build CGM-based type 2 diabetes risk profiles. She is also involved in multiple clinical studies using dynamic CGM metrics to inform clinical care for patients with diabetes - including staging of diabetes as it develops.

Clinically, Dr. Ruiz enjoys caring for all pediatric patients seeking general endocrinology and diabetes care.

A native Texan, Dr. Ruiz obtained a B.S. in Bioengineering from Rice University (Houston, TX). She completed her M.D. at Harvard Medical School in the Harvard-MIT Health Sciences and Technology (HST) program (Boston, MA). She remained at Harvard to complete her training in Pediatrics in the Boston Combined Residency Program (Boston Children's Hospital and Boston Medical Center), followed by her training in Pediatric Endocrinology at Boston Children's Hospital. She was on the faculty at Boston Children's Hospital/Harvard Medical School as an Instructor for 2 years prior to moving to Stanford.

Dr. Ruiz also enjoys mentoring trainees and was formerly a Harvard Medical School Faculty Advisor and Associate Program Director for the Boston Children's Pediatric Endocrinology Fellowship Program.

Professional Education


  • Board Certification, American Board of Pediatrics, Pediatric Endocrinology (2025)
  • Fellowship, Boston Children's Hospital Pediatric Endocrinology Fellowship (2024)
  • Board Certification, American Board of Pediatrics, Pediatrics (2021)
  • Residency, Boston Combined Residency Program, Pediatrics (2021)
  • M.D., Harvard Medical School (2018)
  • B.S., Rice University, Bioengineering (2013)

All Publications


  • Pediatric Inpatient Continuous Glucose Monitor Accuracy by Sensor Wear Day, Hospital Day, and Glucose Rate of Change. Diabetes technology & therapeutics Ruiz, J. L., Stein, A. B., Wheelock, A., Stewart, B., Bernique, A. S., Jost, E., Garvey, K. C., Astley, C. M., Cobry, E. C. 2026: 15209156261486139

    Abstract

    Continuous glucose monitoring (CGM) improves glycemic outcomes but inpatient use in the United States is not FDA approved, despite the potential need for frequent glycemic monitoring during hospitalization. We sought to assess CGM accuracy in the pediatric hospital setting and to evaluate the impact of potential modifiers of accuracy, including sensor wear day, hospitalization day, and glucose changes.In this retrospective cross-sectional accuracy study among youth and young adults with diabetes hospitalized at two pediatric centers, reference point-of-care (POC) capillary glucose values were compared with Dexcom G7 CGM glucose readings (paired within 5 min). Accuracy was assessed using standard metrics, including mean absolute relative difference (MARD) and Parkes error grids, overall, and stratified by sensor wear day, hospital day, and CGM glucose rate of change.We analyzed 544 POC-CGM glucose pairs from 68 participants with diabetes aged 2-22 years (mean 12.4 ± 5.8 years old, 58.8% female, 66.2% White, 8.8% Hispanic) during 80 hospital encounters. The overall MARD was 12.5%. Accuracy was comparable on sensor wear day 1 and days 2-6 (MARD 12.3% vs 13.6%, respectively) and was best on wear days 7-10 (MARD 10.6%). Accuracy improved from hospital day 1 (MARD 13.7%) to hospital days 2-4 and 5-30 (MARD 10.4% and 12.5%, respectively). Overall and on wear day 1, almost all glucose pairs (99%) fell within low-risk Parkes error grid zones A and B. Accuracy was best with a flat [-1 to 1 mg/(dL·min)] rate of change (MARD 11.5%-11.9%) and was reduced with rapidly rising or falling [beyond -2 or 2 mg/(dL·min)] CGM values (MARD 16.6%-18.4%).In this pediatric hospital CGM accuracy study, MARD was within a favorable range of <14% overall and throughout sensor wear and hospitalization. Reduced accuracy with rapidly changing glucose highlights the need to incorporate trend arrows into hospital CGM protocols.

    View details for DOI 10.1177/15209156261486139

    View details for PubMedID 42719887

    View details for PubMedCentralID PMC13623626

  • Continuous glucose monitoring evidence of celiac disease in type 1 diabetes. Journal of pediatric endocrinology & metabolism : JPEM Ruiz, J. L., Asaro, L. A., Bernique, A. S., Healey, E., Silvester, J. A., Wypij, D., Agus, M. S., Astley, C. M. 2025; 38 (11): 1126-1134

    Abstract

    Quantitative glycemic metrics are needed to identify undiagnosed celiac disease in type 1 diabetes and reduce delays in celiac diagnosis. Celiac enteropathy drives malabsorption that increases the risk of prandial insulin-glucose mismatch and hypoglycemia. We assessed if children with type 1 diabetes and celiac disease have lower post-prandial glucose levels preceding celiac diagnosis vs. those without celiac disease, leveraging continuous glucose monitoring (CGM) data and a computational meal annotation algorithm.In this retrospective cohort study, children with type 1 diabetes <12 months duration using CGM, positive celiac serologies and biopsy confirmed celiac disease (n=16) were matched 1-to-4 to those with negative celiac serologies (n=60). Meals were computationally annotated in the 30-day window before serologies. Differences in post-prandial trough glucose and other prandial glycemic outcomes were assessed via mixed models.Undiagnosed celiac disease was associated with a lower glucose rise from meal start to peak vs. no celiac disease (-8.9 %, 95 % CI, -14.9--2.5 %, p=0.009) and, during the first meal of the day, a lower fall from peak to trough (-9.3 %, 95 % CI, -16.5 %--1.5 %, p=0.02). There was no significant association between celiac disease and trough glucose, meal hypoglycemia or time hypoglycemic.Computational analysis revealed that blunted prandial glycemic trajectories, not hypoglycemia, are associated with undiagnosed celiac disease in children with type 1 diabetes using CGM. These findings challenge current guidelines, and future studies should validate and integrate these glycemic biomarkers into a CGM-based model for real-time prediction of celiac disease in type 1 diabetes.

    View details for DOI 10.1515/jpem-2025-0302

    View details for PubMedID 40990290

    View details for PubMedCentralID PMC12574949

  • A case study on using a large language model to analyze continuous glucose monitoring data. Scientific reports Healey, E., Tan, A. L., Flint, K. L., Ruiz, J. L., Kohane, I. 2025; 15 (1): 1143

    Abstract

    Continuous glucose monitors (CGM) provide valuable insights about glycemic control that aid in diabetes management. However, interpreting metrics and charts and synthesizing them into linguistic summaries is often non-trivial for patients and providers. The advent of large language models (LLMs) has enabled real-time text generation and summarization of medical data. The objective of this study was to assess the strengths and limitations of using an LLM to analyze raw CGM data and produce summaries of 14 days of data for patients with type 1 diabetes. We first evaluated the ability of GPT-4 to compute quantitative metrics specific to diabetes found in an Ambulatory Glucose Profile (AGP). Then, using two independent clinician graders, we evaluated the accuracy, completeness, safety, and suitability of qualitative descriptions produced by GPT-4 across five different CGM analysis tasks. GPT-4 performed 9 out of the 10 quantitative metrics tasks with perfect accuracy across all 10 cases. The clinician-evaluated CGM analysis tasks had good performance across measures of accuracy [lowest task mean score 8/10, highest task mean score 10/10], completeness [lowest task mean score 7.5/10, highest task mean score 10/10], and safety [lowest task mean score 9.5/10, highest task mean score 10/10]. Our work serves as a preliminary study on how generative language models can be integrated into diabetes care through data summarization and, more broadly, the potential to leverage LLMs for streamlined medical time series analysis.

    View details for DOI 10.1038/s41598-024-84003-0

    View details for PubMedID 39774031

    View details for PubMedCentralID PMC11707017

  • Hispanic Caregivers' experience of pediatric type 1 diabetes: A qualitative study. Pediatric diabetes Tremblay, E. S., Ruiz, J., Dykeman, B., Maldonado, M., Garvey, K. 2021; 22 (7): 1040-1050

    Abstract

    It is widely recognized that Type 1 Diabetes (T1D) outcomes are worse among Hispanic children; however, little is published about the perspectives of these patients and their caregivers. Our intent was to characterize the lived experience of Hispanic caregivers of children with T1D, focusing on the role of language and culture and their perspectives on current medical care and alternative care models. We studied Hispanic caregivers of patients (age 2-17 years) with T1D of greater than 6 months' duration.We completed semi-structured interviews and focus-groups of a purposive sample of 20 members of our population of interest. We developed a codebook and completed multidisciplinary consensus coding, then conducted iterative thematic analysis using qualitative software and discussion to generate themes.We gathered data from 20 Hispanic caregivers of T1D patients (11.37 ± 3.00 years old, 4.80 ± 2.84 years since diagnosis). 85% of caregivers were female, 80% preferred Spanish, and 15% were college-educated. Our analysis yielded 4 themes across the participants: (1) Culturally-based nutrition challenges, (2) Social isolation and lack of support for T1D care, (3) Hesitancy to fully embrace diabetes technology, and (4) Deferential views of care experience and providers. Overarching all of these themes was support for Hispanic group-based models of care tailored to address these concerns.The unique concerns among Hispanic caregivers of children with T1D suggest the importance of culturally tailored interventions to improve care. With successful implementation, such interventions could diminish widening disparities in healthcare outcomes.

    View details for DOI 10.1111/pedi.13247

    View details for PubMedID 34232537

    View details for PubMedCentralID PMC8530860

  • Nanoanalytical analysis of bisphosphonate-driven alterations of microcalcifications using a 3D hydrogel system and in vivo mouse model. Proceedings of the National Academy of Sciences of the United States of America Ruiz, J. L., Hutcheson, J. D., Cardoso, L., Bakhshian Nik, A., Condado de Abreu, A., Pham, T., Buffolo, F., Busatto, S., Federici, S., Ridolfi, A., Aikawa, M., Bertazzo, S., Bergese, P., Weinbaum, S., Aikawa, E. 2021; 118 (14)

    Abstract

    Vascular calcification predicts atherosclerotic plaque rupture and cardiovascular events. Retrospective studies of women taking bisphosphonates (BiPs), a proposed therapy for vascular calcification, showed that BiPs paradoxically increased morbidity in patients with prior acute cardiovascular events but decreased mortality in event-free patients. Calcifying extracellular vesicles (EVs), released by cells within atherosclerotic plaques, aggregate and nucleate calcification. We hypothesized that BiPs block EV aggregation and modify existing mineral growth, potentially altering microcalcification morphology and the risk of plaque rupture. Three-dimensional (3D) collagen hydrogels incubated with calcifying EVs were used to mimic fibrous cap calcification in vitro, while an ApoE-/- mouse was used as a model of atherosclerosis in vivo. EV aggregation and formation of stress-inducing microcalcifications was imaged via scanning electron microscopy (SEM) and atomic force microscopy (AFM). In both models, BiP (ibandronate) treatment resulted in time-dependent changes in microcalcification size and mineral morphology, dependent on whether BiP treatment was initiated before or after the expected onset of microcalcification formation. Following BiP treatment at any time, microcalcifications formed in vitro were predicted to have an associated threefold decrease in fibrous cap tensile stress compared to untreated controls, estimated using finite element analysis (FEA). These findings support our hypothesis that BiPs alter EV-driven calcification. The study also confirmed that our 3D hydrogel is a viable platform to study EV-mediated mineral nucleation and evaluate potential therapies for cardiovascular calcification.

    View details for DOI 10.1073/pnas.1811725118

    View details for PubMedID 33795519

    View details for PubMedCentralID PMC8040669

  • Health Care Transition in Youth With Type 1 Diabetes and an A1C >9%: Qualitative Analysis of Pre-Transition Perspectives. Diabetes spectrum : a publication of the American Diabetes Association Tremblay, E. S., Ruiz, J., Buccigrosso, T., Dean, T., Garvey, K. 2020; 33 (4): 331-338

    Abstract

    OBJECTIVE | To explore expectations for transition to adult care and experiences with transition planning among adolescents and young adults with type 1 diabetes and an A1C >9% at a tertiary care U.S. pediatric center. METHODS | We conducted semi-structured interviews in a purposive sample of patients 14-23 years of age who had had type 1 diabetes for at least 1 year and had an A1C >9%. A multidisciplinary team conducted iterative thematic analysis with deductive and inductive coding aided by NVivo software. RESULTS | Fourteen subjects participated (nine adolescents and five young adults, mean age 17.1 ± 3.2 years, 57% male, 79% Caucasian, 14% Hispanic, diabetes duration 8.2 ± 4.6 years, mean A1C 10.0 ± 0.8% for adolescents and 10.1 ± 0.7% for young adults). Qualitative analysis yielded four key themes. The first was lack of formal preparation; participants of all ages demonstrated a lack of preparation for transition and ignorance about the process, describing it as coming "out of the blue." The second was a desire for delayed and gradual transition; participants wanted to defer being "serious" about transition to a later/uncertain date, with a preference to "wait until I'm older" among all ages. Participants described ideal transition as a gradual process, taking place "a little at a time." The third was attachment to pediatric providers; participants demonstrated a nearly universal attachment to and "familiarity" with their pediatric diabetes care providers and expressed worries about an "uncomfortable" transition to adult providers. The fourth was concern about an impersonal adult care setting: participants perceived adult care as "formal," "scarier," and "tougher," with increased criticism about poor control; participants expressed fear that adult providers would not "know me" or appreciate "my diabetes journey." CONCLUSION | We demonstrated a lack of transition preparation and anxiety about transition and adult care among youth with type 1 diabetes and elevated A1C. Our results may help guide early, iterative pediatric transition counseling, with a special focus on addressing attachment and fears about adult diabetes care.

    View details for DOI 10.2337/ds20-0011

    View details for PubMedID 33223771

    View details for PubMedCentralID PMC7666607

  • Zooming in on the genesis of atherosclerotic plaque microcalcifications. The Journal of physiology Ruiz, J. L., Weinbaum, S., Aikawa, E., Hutcheson, J. D. 2016; 594 (11): 2915-27

    Abstract

    Epidemiological evidence conclusively demonstrates that calcium burden is a significant predictor of cardiovascular morbidity and mortality; however, the underlying mechanisms remain largely unknown. These observations have challenged the previously held notion that calcification serves to stabilize the atherosclerotic plaque. Recent studies have shown that microcalcifications that form within the fibrous cap of the plaques lead to the accrual of plaque-destabilizing mechanical stress. Given the association between calcification morphology and cardiovascular outcomes, it is important to understand the mechanisms leading to calcific mineral deposition and growth from the earliest stages. We highlight the open questions in the field of cardiovascular calcification and include a review of the proposed mechanisms involved in extracellular vesicle-mediated mineral deposition.

    View details for DOI 10.1113/JP271339

    View details for PubMedID 27040360

    View details for PubMedCentralID PMC4887667

  • Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques NATURE MATERIALS Hutcheson, J. D., Goettsch, C., Bertazzo, S., Maldonado, N., Ruiz, J. L., Goh, W., Yabusaki, K., Faits, T., Bouten, C., Franck, G., Quillard, T., Libby, P., Aikawa, M., Weinbaum, S., Aikawa, E. 2016; 15 (3): 335-+

    Abstract

    Clinical evidence links arterial calcification and cardiovascular risk. Finite-element modelling of the stress distribution within atherosclerotic plaques has suggested that subcellular microcalcifications in the fibrous cap may promote material failure of the plaque, but that large calcifications can stabilize it. Yet the physicochemical mechanisms underlying such mineral formation and growth in atheromata remain unknown. Here, by using three-dimensional collagen hydrogels that mimic structural features of the atherosclerotic fibrous cap, and high-resolution microscopic and spectroscopic analyses of both the hydrogels and of calcified human plaques, we demonstrate that calcific mineral formation and maturation results from a series of events involving the aggregation of calcifying extracellular vesicles, and the formation of microcalcifications and ultimately large calcification areas. We also show that calcification morphology and the plaque's collagen content-two determinants of atherosclerotic plaque stability-are interlinked.

    View details for DOI 10.1038/nmat4519

    View details for Web of Science ID 000370967400020

    View details for PubMedID 26752654

    View details for PubMedCentralID PMC4767675

  • Cardiovascular calcification: current controversies and novel concepts. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology Ruiz, J. L., Hutcheson, J. D., Aikawa, E. 2015; 24 (4): 207-12

    Abstract

    Cardiovascular calcification is a commonly observed but incompletely understood mechanism of increased atherosclerotic plaque instability and accelerated aortic valve stenosis. Traditional histological staining and imaging techniques are nonspecific for the type of mineral present in calcified tissues, information that is critical for proper validation of in vitro and in vivo models. This review highlights current gaps in our understanding of the biophysical implications and the cellular mechanisms of valvular and vascular calcification and how they may differ between the two tissue types. We also address the hindrances of current cell culture systems, discussing novel platforms and important considerations for future studies of cardiovascular calcification.

    View details for DOI 10.1016/j.carpath.2015.03.002

    View details for PubMedID 25797772

  • Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes care Weinzimer, S. A., Sherr, J. L., Cengiz, E., Kim, G., Ruiz, J. L., Carria, L., Voskanyan, G., Roy, A., Tamborlane, W. V. 2012; 35 (10): 1994-9

    Abstract

    Even under closed-loop (CL) conditions, meal-related blood glucose (BG) excursions frequently exceed target levels as a result of delays in absorption of insulin from the subcutaneous site of infusion. We hypothesized that delaying gastric emptying with preprandial injections of pramlintide would improve postprandial glycemia by allowing a better match between carbohydrate and insulin absorptions.Eight subjects (4 female; age, 15-28 years; A1C, 7.5 ± 0.7%) were studied for 48 h on a CL insulin-delivery system with a proportional integral derivative algorithm with insulin feedback: 24 h on CL control alone (CL) and 24 h on CL control plus 30-μg premeal injections of pramlintide (CLP). Target glucose was set at 120 mg/dL; timing and contents of meals were identical on both study days. No premeal manual boluses were given. Differences in reference BG excursions, defined as the incremental glucose rise from premeal to peak, were compared between conditions for each meal.CLP was associated with overall delayed time to peak BG (2.5 ± 0.9 vs. 1.5 ± 0.5 h; P < 0.0001) and reduced magnitude of glycemic excursion (88 ± 42 vs. 113 ± 32 mg/dL; P = 0.006) compared with CL alone. Pramlintide effects on glycemic excursions were particularly evident at lunch and dinner, in association with higher premeal insulin concentrations at those mealtimes.Pramlintide delayed the time to peak postprandial BG and reduced the magnitude of prandial BG excursions. Beneficial effects of pramlintide on CL may in part be related to higher premeal insulin levels at lunch and dinner compared with breakfast.

    View details for DOI 10.2337/dc12-0330

    View details for PubMedID 22815298

    View details for PubMedCentralID PMC3447854

  • Effect of insulin feedback on closed-loop glucose control: a crossover study. Journal of diabetes science and technology Ruiz, J. L., Sherr, J. L., Cengiz, E., Carria, L., Roy, A., Voskanyan, G., Tamborlane, W. V., Weinzimer, S. A. 2012; 6 (5): 1123-30

    Abstract

    Closed-loop (CL) insulin delivery systems utilizing proportional-integral-derivative (PID) controllers have demonstrated susceptibility to late postprandial hypoglycemia because of delays between insulin delivery and blood glucose (BG) response. An insulin feedback (IFB) modification to the PID algorithm has been introduced to mitigate this risk. We examined the effect of IFB on CL BG control.Using the Medtronic ePID CL system, four subjects were studied for 24 h on PID control and 24 h during a separate admission with the IFB modification (PID + IFB). Target glucose was 120 mg/dl; meals were served at 8:00 AM, 1:00 PM, and 6:00 PM and were identical for both admissions. No premeal manual boluses were given. Reference BG excursions, defined as incremental glucose rise from premeal to peak, and postprandial BG area under the curve (AUC; 0-5 h) were compared. Results are reported as mean ± standard deviation.The PID + IFB control resulted in higher mean BG levels compared with PID alone (153 ± 54 versus 133 ± 56 mg/dl; p < .0001). Postmeal BG excursions (114 ± 28 versus 114 ± 47 mg/dl) and AUCs (285 ± 102 versus 255 ± 129 mg/dl/h) were similar under both conditions. Total insulin delivery averaged 57 ± 20 U with PID versus 45 ± 13 U with PID + IFB (p = .18). Notably, eight hypoglycemic events (BG < 60 mg/dl) occurred during PID control versus none during PID + IFB.Addition of IFB to the PID controller markedly reduced the occurrence of hypoglycemia without increasing meal-related glucose excursions. Higher average BG levels may be attributable to differences in the determination of system gain (Kp) in this study. The prevention of postprandial hypoglycemia suggests that the PID + IFB algorithm may allow for lower target glucose selection and improved overall glycemic control.

    View details for DOI 10.1177/193229681200600517

    View details for PubMedID 23063039

    View details for PubMedCentralID PMC3570847